<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164880">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004197</url>
  </required_header>
  <id_info>
    <org_study_id>Asif-HP-001</org_study_id>
    <nct_id>NCT02004197</nct_id>
  </id_info>
  <brief_title>Quadruple and Phytomedicine-based Therapies in H. Pylori Infection</brief_title>
  <official_title>Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hafiz Muhammad Asif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shifa Ul Mulk Memorial Hospital</source>
  <oversight_info>
    <authority>Pakistan: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori is strongly associated to the development of gastrointestinal disorders.
      Emerging antibiotic resistance and poor patient compliance of modern therapies has resulted
      in significant eradication failure. Clinical trial was conducted to see the efficacy of
      current quadruple and phytomedicine-based therapies for the eradication of H. pylori
      infection and relief in its associated symptoms in Pakistan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>H. pylori eradication rate was the primary endpoint, which was considered to be achieved on the basis of a negative urea breath and stool antigen test four weeks after the end of treatment</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint was the improvement in the clinical features as assessed by an improvement in dyspepsia scores</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Helicobacter Pylori [H. Pylori] as the Cause of Diseases</condition>
  <arm_group>
    <arm_group_label>Pylorex plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pylorex plus consisting of medicinal plants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadruple Allopathic therapy</intervention_name>
    <arm_group_label>Pylorex plus</arm_group_label>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Omeprazol</other_name>
    <other_name>Amoxicillin</other_name>
    <other_name>Metronodazole</other_name>
    <other_name>TRITEC (ranitidine bismuth citrate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pylorex plus</intervention_name>
    <arm_group_label>Pylorex plus</arm_group_label>
    <arm_group_label>Quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients suffering from H. pylori infection

          2. Patients having no previous record of treatment against H. pylori infection

          3. Patients living in Karachi, Rawalpindi and Bahawalpur

          4. Patients having no pathological complications on routine examination

          5. All socioeconomic classes were included in the study

          6. Male and female patients between 15 to 45 years of age

        Exclusion Criteria:

          1. there was peptic ulceration, gastrointestinal bleeding or gastric carcinoma

          2. if history of use of antibiotics, proton-pump inhibitors or bismuth compound in the
             last one month before test

          3. any patient found to be allergic or intolerant to therapeutic regimens

          4. they failed to report for follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khan Usman Ghani, Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Hamdard University Karachi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>clinical trial was conducted in high risk areas of Pakistan such as Karachi, Bahawalpur, Islamabad and Rawalpindi at Shifa-Ul-Mulk Memorial Hospital, Hamdrad University Karachi, Bahawalpur Victoria Hospital and Nawaz Salik Hospital respectively</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shifa Ul MUlk Memorial Hospital</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>August 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shifa Ul Mulk Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Hafiz Muhammad Asif</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
